April 30, 2008 - Entelos, Inc. (LSE:ENTL) a leading life sciences company building predictive computer models of human physiology and "virtual patients" for drug discovery and development, announced that Eli Lilly and Company (“Lilly”) has signed an agreement with Entelos to conduct in silico research in the field of diabetes using the Entelos® Metabolism PhysioLab® platform. Financial terms were not disclosed.
The Entelos Metabolism PhysioLab platform is an innovative and predictive computer model that simulates diabetic patients and can accurately predict the effects of drugs, changes in diet and exercise, and other interventions... Entelos' Press Release -
